Intradigm this month announced several new managerial appointments as part of a reorganization (see related story, this issue).
The company said that it has named Steven Chamow senior vice president of chemistry, manufacturing, and control.
Chamow was most recently vice president of process sciences at antibody-based cancer drug developer Genitope. Before this he served as vice president of process sciences at Abgenix. He holds a BA in biology from the University of California, Santa Cruz and a PhD in biochemistry from UC Davis.
Intradigm also recently named Xiao-Dong Yang vice president of research and preclinical development.
Prior to joining the company, Yang was senior director of cancer pharmacology at Abgenix. He holds an MD from Beijing Medical University and a PhD in immunology from the University of Bern.
Mohammad Azab has also joined Intradigm as president and CEO, replacing former CEO John Spears.
Azab was most recently chief medical officer at QLT. He holds an MBA from theRichard Ivey School of Business, University of Western Ontario and an MD from Cairo University.
Intradigm also said that Mike Riley has joined the company as vice president of corporate development.
Previously, Riley held various positions with Amgen, Abgenix, and Celltech. He holds a JD from the University of North Dakota School of Law and an MSc in biochemistry/molecular biology from the university’s school of medicine.
Lentigen said this week that it has appointed Adam Sachs as president of commercial operations.
Sachs has held senior management positions at Life Technologies, Qiagen, and OriGene. He has a BS in chemistry from the University of Michiganand an MSE in chemical engineering from the University of California, San Diego.